IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 901-925 out of 1318.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

Public Release: 24-Apr-2015
American Roentgen Ray Society (ARRS) 2015 Annual Meeting
DBT dramatically improves cancer detection rate in dense breast tissue
Digital breast tomosynthesis (DBT) increases the rate of cancer detection in women with dense breast tissue by as much as 67 percent, according to new research from the Einstein Medical Center in Philadelphia.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 24-Apr-2015
American Roentgen Ray Society (ARRS) 2015 Annual Meeting
FDG PET/CT not useful in staging newly diagnosed stage III invasive lobular breast cancer
Although National Comprehensive Cancer Network guidelines consider 18F-PET/CT appropriate for systemic staging of newly diagnosed stage III breast cancer, the technique may not be equally valuable for all breast cancer histologies.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 23-Apr-2015
ecancermedicalscience
Cures and curcumin -- turmeric offers potential therapy for oral cancers
Curcumin, an antioxidant found in the common spice turmeric, has been found to limit the activity of human papillomavirus in oral cancer cells.

Contact: Audrey Nailor
audrey@ecancer.org
44-117-909-4608
ecancermedicalscience

Public Release: 23-Apr-2015
American Surgical Association's 135th Annual Meeting
Annals of Surgery
Eligible for breast conserving therapy, many still choose mastectomy
New research led by Brigham and Women's Hospital finds that breast conserving therapy -- or the removal of less breast tissue via a lumpectomy -- was successful in more than 90 percent of patients with triple-negative breast cancer who became eligible for this procedure after treatment with chemotherapy. Despite these findings, 31 percent who were eligible for breast conserving therapy chose to have the entire breast removed via mastectomy.
NIH/National Cancer Institute

Contact: Elaine St. Peter
estpeter@partners.org
617-525-6375
Brigham and Women's Hospital

Public Release: 23-Apr-2015
Cell
Brain tumor growth stimulated by nerve activity in the cortex, Stanford study finds
Deadly brain tumors called high-grade gliomas grow with the help of nerve activity in the cerebral cortex, according to a new study by researchers at the Stanford University School of Medicine.
NIH/National Institute of Neurological Disorders and Stroke, McKenna Claire Foundation, Matthew Larson Foundation, National Science Foundation, Godfrey Family Fund in Memory of Fiona Penelope, California Institute for Regenerative Medicine

Contact: Erin Digitale
digitale@stanford.edu
650-724-9175
Stanford University Medical Center

Public Release: 23-Apr-2015
Nature Genetics
Hundreds of cancer possibilities arise from common skin mole mutation
A team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas.
National Cancer Institute, Agency for Science, Technology, and Research, Singapore,Cancer Prevention Research Institute of Texas, Health Research Council of New Zealand, University of Auckland, New Zealand Maurice Wilkins Centre, Melanoma Research Allianc

Contact: David Bricker
dmbricker@houstonmethodist.org
832-667-5811
Houston Methodist

Public Release: 23-Apr-2015
JAMA Oncology
Oophorectomy associated with decrease in breast cancer death in women with cancer, BRCA1 mutation
Removal of the ovaries, a procedure known as an oophorectomy, was associated with a 62 percent reduction in breast cancer death in women diagnosed with breast cancer and carrying a BRCA1 gene mutation, according to an article published online by JAMA Oncology.

Contact: Rebecca Cheung
Rebecca.Cheung@wchospital.ca
416-323-6400 x3210
The JAMA Network Journals

Public Release: 23-Apr-2015
PLOS Computational Biology
Chance and circumstance tip immune control of cancer
A team of Northwestern University researchers developed a new computational model that elucidates the dynamic interplay between cancer and the immune system.

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 23-Apr-2015
Pain
An end to cancer pain?
A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fueled cancers.

Contact: Erin Vollick
erin.vollick@dentistry.utoronto.ca
41-697-949-004-381
University of Toronto - Faculty of Dentistry

Public Release: 23-Apr-2015
Oncogene
'Humanized' mice will lead to better testing of cancer immunotherapies
New model reported in Oncogene, XactMice, uses human blood stem cells to grow a 'humanized' mouse immune system prior to tumor transplantation, allowing anti-cancer therapies to be tested in a much more human-like environment.
US Department of Defense, National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 23-Apr-2015
Nature Reviews Clinical Oncology
The past, present and future of pancreatic cancer research and treatment
Oncologists at the CNIO and the Huntsman Cancer Institute reviewed close to 200 scientific articles about this type of tumor that have been published over the past 30 years. The review addresses questions such as the use of immunotherapy or the possible systemic origin of this illness. Pancreatic cancer is rare, but it is one of the most deadly cancers with the highest mortality rates, and one of the lowest five-year survival rates.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 22-Apr-2015
Science Translational Medicine
A promising step forward toward a new treatment against cancer
The work of UCL researchers, published on April 22 in the prestigious scientific magazine Science Translational Medicine, allows taking into consideration new methods of immunotherapy against cancer, which could lead to an improvement of the efficiency of the current treatment methods.
WELBIO

Contact: Sophie Lucas
sophie.lucas@uclouvain.be
32-276-47474
Université catholique de Louvain

Public Release: 22-Apr-2015
Science Translational Medicine
Microinjection platform tests multiple cancer drugs in tumors, predicts systemic response
A newly developed technology for evaluating multiple cancer drugs or combinations while a tumor is still in a patient's body has been shown to accurately predict systemic response to the drugs, according to researchers at Fred Hutchinson Cancer Research Center, Presage Biosciences and Celgene. The patented technology, CIVO™, consists of an arrayed microinjection drug delivery device and quantitative analysis methodology tested in xenografted mouse models, canine patients and an ongoing first-in-human study.
Presage Biosciences

Contact: Kira Gordon
kira@proncall.com
646-243-4920
PR on Call

Public Release: 22-Apr-2015
American Association for Cancer Research Annual Meeting 2015
FACC-29 gathers authenticated canine cancer cell lines for research and drug development
Members of the University of Colorado Cancer Center report at the American Association for Cancer Research Annual Meeting 2015 the assembly of a panel of validated canine cancer cell lines named the FACC-29, analogous to the NCI-60.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Anschutz Medical Campus

Public Release: 22-Apr-2015
American Roentgen Ray Society (ARRS) 2015 Annual Meeting
Breast arterial calcification strong predictor of coronary artery calcification
In a study to ascertain whether breast arterial calcification (BAC) detected with digital mammography correlates to chest CT findings of coronary artery calcification (CAC), researchers have discovered a striking relationship between the two factors. In 76 percent of the study cohort, women who had a BAC score of 0 also had a CAC score of 0. As the BAC score increases, there is a concomitant increase in the CAC score.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 22-Apr-2015
New England Journal of Medicine
Cancer scan could remove need for radiotherapy for cured patients
A UK National Cancer Research Institute trial led from The University of Manchester and the Christie NHS Foundation Trust has suggested that in patients with early stage Hodgkin's lymphoma the late effects of radiotherapy could be reduced by using a scan to determine those who actually need it.
Leukemia and Lymphoma Research

Contact: Jamie Brown
jamie.brown@manchester.ac.uk
44-161-275-8383
University of Manchester

Public Release: 22-Apr-2015
American Association for Cancer Research Annual Meeting 2015
Triple negative breast cancer in African-American women has distinct difference
What makes triple negative breast cancer more lethal in African-American women than white women or women of European descent? A new study reveals specific genetic alterations that appears to impact their prognosis and ultimately survival rates.
US Food and Drug Administration

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 22-Apr-2015
Thyroid
First guidelines from the American Thyroid Associationn: Managing thyroid nodules and cancer in children
Previous guidelines from the American Thyroid Association (ATA) for evaluating and managing thyroid nodules and thyroid cancers targeted adults. Recognizing the potential differences in clinical presentation and long-term outcomes, and the potential risks of overly aggressive therapy in pediatric patients with thyroid cancer, an ATA Task Force developed management guidelines for children with thyroid nodules and differentiated thyroid cancer, which are published in Thyroid.

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 22-Apr-2015
Nature
Toxic mushroom-based drug may help battle colorectal cancer
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from 'death cap' mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 22-Apr-2015
Nature Scientific Reports
Study illuminates role of cancer drug decitabine in repairing damaged cells
A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.
National Institutes of Health, National Cancer Institute/Cancer Prevention Internship Program, Indiana Clinical and Translational Sciences Institute

Contact: Natalie van Hoose
nvanhoos@purdue.edu
765-496-2050
Purdue University

Public Release: 22-Apr-2015
Science Translational Medicine
Personalized cancer treatment
MIT researchers develop implantable device that could allow doctors to test cancer drugs in patients before prescribing chemotherapy.
Kibur Medical, NIH/National Cancer Institute

Contact: Sarah McDonnell
s_mcd@mit.edu
617-827-7637
Massachusetts Institute of Technology

Public Release: 22-Apr-2015
Journal of Molecular Diagnostics
The Association for Molecular Pathology compiles current research on liquid biopsy
In general, the article supports the notion that this type of diagnostic testing in and of itself allows for earlier diagnosis, faster and more targeted treatment, reduced costs, and increased quality of life and even increased lifespan for the patient.

Contact: Nicole Litchfield
nicole@bioscribe.com
415-793-6468
Association for Molecular Pathology

Public Release: 22-Apr-2015
Gastroenterology
Updates in liver disease research: Do you want the good or bad news?
The May issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important research updates on the most deadly forms of liver disease.

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association

Public Release: 22-Apr-2015
Science Signaling
New therapeutic target for a type of colorectal cancer with poor prognosis has been identified
Researchers at the Institut Hospital del Mar d'Investigacions Mèdiques have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by Luís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene.

Contact: Marta Calsina
mcalsina@imim.es
34-933-160-680
IMIM (Hospital del Mar Medical Research Institute)

Public Release: 21-Apr-2015
Immunity
Protein identified that serves as a 'brake' on inflammation
Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis, colitis and other autoimmune disorders. St. Jude Children's Research Hospital scientists led the study which appears today in the scientific journal Immunity.
National Institutes of Health, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Showing releases 901-925 out of 1318.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

  Search News Releases

     

 

EurekAlert!